Inquiry Basket
MAC-VC-PABC-ST7612AA1 is part of Antibody Drug Conjugate ADCs with HDAC inhibitor payload and linker for antitumor activity.
| Catalog Number | Size | Price | Quantity | |
|---|---|---|---|---|
| BADC-01472 | -- | $-- | Inquiry |
MAC-VC-PABC-ST7612AA1 is a conjugate used in the development of targeted cancer therapies, specifically in antibody-drug conjugates (ADCs). This compound combines a potent cytotoxic agent, ST7612AA1, with a linker system designed to ensure selective release of the drug at the tumor site. The linker includes a cleavable peptide bond, allowing for the controlled release of ST7612AA1 upon internalization into cancer cells. The VC (valine-citrulline) peptide provides tumor-specific enzymatic cleavage by lysosomal enzymes, ensuring that the drug is released only in the cancerous tissue. This targeted approach enhances the therapeutic effect by delivering the cytotoxic agent directly to tumor cells while minimizing systemic toxicity.
Another key application of MAC-VC-PABC-ST7612AA1 is in overcoming drug resistance in cancer therapies. Many cancers develop resistance to traditional chemotherapies due to factors like drug efflux or reduced cellular uptake. By using a targeted ADC system like MAC-VC-PABC-ST7612AA1, the therapeutic agent is specifically delivered to the cancer cells, bypassing resistance mechanisms such as multidrug resistance proteins. This ensures that the full therapeutic potential of ST7612AA1 is realized in resistant cancer cells, providing a more effective treatment option for patients with drug-resistant tumors. This is especially relevant for cancers such as ovarian, breast, and lung cancer, which often exhibit resistance to standard therapies.
MAC-VC-PABC-ST7612AA1 also shows promise in combination therapies, where it can be paired with other treatment modalities to enhance overall efficacy. For example, when combined with immune checkpoint inhibitors or targeted therapies, MAC-VC-PABC-ST7612AA1 can help to reduce the tumor burden while also modulating the immune response. The selective release of the cytotoxic agent within the tumor microenvironment could synergize with immunotherapy, making the immune cells more effective at attacking the tumor. This combination approach has the potential to provide more durable and effective cancer treatment, particularly in aggressive or late-stage cancers.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
